DXCM vs BIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 12, 2026

DXCM

35.0
AI Score
VS
BIO Wins

BIO

37.3
AI Score

Investment Advisor Scores

DXCM

35score
Recommendation
SELL

BIO

37score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DXCM BIO Winner
Revenue 2.50B 1.24B DXCM
Net Income 448.60M -155.70M DXCM
Gross Margin 63.2% 52.7% DXCM
Net Margin 17.9% -12.5% DXCM
Operating Income 573.60M 106.70M DXCM
ROE 17.1% -2.2% DXCM
ROA 6.9% -1.5% DXCM
Total Assets 6.46B 10.25B BIO
Cash 1.10B 517.00M DXCM
Current Ratio 1.73 3.14 BIO
Free Cash Flow 633.50M 144.80M DXCM

Relative Price Performance (Last 90 Days)

DXCM 1M: +17.3% · 3M: +50.9% BIO 1M: +19.7% · 3M: +46.1%

Current Technical Phase

DXCM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 70

RSI (14): 70.1 · Price: $89.53

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 75

RSI (14): 75.4 · Price: $356.25

Fundamentals Snapshot

Metric DXCM BIO
Market Cap
Forward P/E 28.7 35.5
Trailing P/E 33.5 42.9
Revenue (TTM)
Revenue Growth 0.1% 0.0%
Gross Margin 0.6% 0.5%
Operating Margin 0.2% 0.1%
EPS 2.62 8.26
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.